The present disclosure provides boron-containing diacylhydrazines having Formula I: ##STR00001##
and the pharmaceutically acceptable salts and solvates thereof, wherein A, R.sup.4, and R.sup.5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.

The present disclosure provides boron-containing diacylhydrazines having Formula I: ##STR00001##
and the pharmaceutically acceptable salts and solvates thereof, wherein A, R.sup.4, and R.sup.5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.

The present invention relates to solid forms of a substituted benzoxaborole compound, specifically crystalline forms of a compound of formula I,

##STR00001##

compositions comprising crystalline forms of the compound of formula (I), and methods of their use.

The present invention relates to solid forms of a substituted benzoxaborole compound, specifically crystalline forms of a compound of formula I,

##STR00001##

compositions comprising crystalline forms of the compound of formula (I), and methods of their use.

The present invention relates to solid forms of a substituted benzoxaborole compound, specifically crystalline forms of a compound of formula I,

##STR00001##

compositions comprising crystalline forms of the compound of formula (I), and methods of their use.

Disclosed herein are boronate intermediates in the synthesis of antimicrobial compounds and the use and preparation thereof. Some embodiments relate to crystalline boronate salt derivatives and their use in the synthesis of therapeutic compounds.

Disclosed herein are boronate intermediates in the synthesis of antimicrobial compounds and the use and preparation thereof. Some embodiments relate to crystalline boronate salt derivatives and their use in the synthesis of therapeutic compounds.

1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof.

1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof.

The present invention relates to an insecticide compound and container device primarily comprised of at least one insecticide compound and at least one container that stores the compound while in use. The compound is preferably comprised of onion, flour, sugar, and boric acid that creates an insecticide that is not harmful to humans. The compound is stored within a base of the container. The container may be comprised of at least one fastener to allow the container to be secured to any surface in any location.